Patent Law Weblog
recent posts
- USPTO Moves to Protect Design Rights for Digital Innovations
- Judicial Conduct and Disability Committee Has Its Say, Denies Judge Newman’s Latest Request for Review
- PTAB Issues Judgment on Priority in CRISPR Interference
- Parties File Supplemental Priority Statements in CRISPR Interference
- Why the Alice Test is Stupid, Part V: The Goalposts Keep Moving
about
Month: June 2009
-
By Kevin E. Noonan — Last week, the Federal Trade Commission issued a report on follow-on biologics ("Emerging Health Care Issues: Follow-on Biologic Drug Competition"). As many patent practitioners did a few years ago when the FTC issued a report on patent reform, many in the biotech and pharma community, generics companies, and Congress…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Medicis Pharmaceutical Corp. v. Ranbaxy Inc. et al.1:09-cv-00435; filed June 11, 2009 in the District Court of Delaware Infringement of U.S. Patent…
-
June 16-17, 2009 – Biotech Patenting (C5) – Munich, Germany June 17, 2009 – The Future of Reverse Payment Settlements: Insider's Guide to Imminent Antitrust Policy Changes (American Conference Institute) – 1:00-2:30 PM (EST) June 19, 2009 – Patent Enforcement & Early Stage Litigation (Law Seminars International) – San Francisco, CA June 22-27, 2009 –…
-
By Donald Zuhn — While the recession has certainly had an effect on biotech/pharma patent filings, the recession appears to have had little impact on lobbying expenditures in the biotech/pharma industry. With the reporting period for first quarter lobbying now passed, many biotech/pharma companies and organizations not only kept pace with, but handily surpassed,…
-
As we noted last month, American Conference Institute (ACI) will be holding the next installment of its FDA Boot Camp conference on July 21-22, 2009 in Chicago, IL. Designed to provide patent attorneys with a comprehensive overview of the basics of Fodd and Drug Administration law, this conference will help attendees gain a better understanding…
-
By Donald Zuhn — Last February, the U.S. Patent and Trademark Office hosted a roundtable discussion on deferred examination. The roundtable, which lasted about four hours, brought together two dozen participants, representing a variety of industries and organizations (as well as positions on the issue), to discuss the advantages and disadvantages of implementing a…
-
By Donald Zuhn — The Federal Circuit today affirmed-in-part and vacated-in-part an order by the District Court for the Northern District of West Virginia awarding $1,011,712 in costs to Plaintiff-Appellee Daiichi Pharmaceutical Co., and remanded to the District Court for an apportionment determination of the awarded costs. Daiichi owns U.S. Patent No. 5,053,407, which…
-
By Donald Zuhn — Last Thursday, authorities on patent law and public policy were brought together to discuss the intersection of cutting-edge genetic research and intellectual property. The discussion, prompted by the recent ACLU v. USPTO case, took place on The Kojo Nnamdi Show on WAMU, Washington, DC's leading public radio station, and those…
-
By Kevin E. Noonan — If behavior can inform belief, it may be getting less and less likely that H.R. 1427, the "Promoting Innovation and Access to Life-Saving Medicine Act," has any reasonable chance of passing in this Congress. The bill, introduced on March 11, 2009 by House Committee on Energy and Commerce Chairman…
-
By Suresh Pillai — Par Files Amended Complaint in Nascobal® Suit Par Pharmaceuticals filed an amended complaint against Fleming & Co. Pharmaceuticals, alleging patent and trademark infringement and unfair competition over Par's prescription nasal spray, Nascobal®. The patent-in-suit, U.S. Patent No. 7,404,489, covers Par's spray-based vitamin B-12 product that was designed as an alternative…
Patent Docs 